166 related articles for article (PubMed ID: 27317590)
1. NICE approves immunotherapy combination for advanced melanoma.
Wise J
BMJ; 2016 Jun; 353():i3421. PubMed ID: 27317590
[No Abstract] [Full Text] [Related]
2. Adoption of ipilimumab in the United States: a Medicare study.
Yao N; Jang S
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):439-40. PubMed ID: 27097117
[No Abstract] [Full Text] [Related]
3. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
Goldstein DA; Zeichner SB
Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
[TBL] [Abstract][Full Text] [Related]
4. Combination Immunotherapy for Melanoma.
Kaufman HL
JAMA Oncol; 2015 Jun; 1(3):387-8. PubMed ID: 26181189
[No Abstract] [Full Text] [Related]
5. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
6. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
7. Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Tsai KK; Daud AI
J Hematol Oncol; 2015 Oct; 8():123. PubMed ID: 26518223
[TBL] [Abstract][Full Text] [Related]
8. Combined immunotherapy improves survival in metastatic melanoma.
Mayor S
BMJ; 2015 Jun; 350():h2993. PubMed ID: 26036979
[No Abstract] [Full Text] [Related]
9. FDA approves new treatment of metastatic melanoma.
Printz C
Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061518
[No Abstract] [Full Text] [Related]
10. Highlights from the ASCO annual meeting.
Printz C
Cancer; 2013 Sep; 119(17):3104-5. PubMed ID: 24037669
[No Abstract] [Full Text] [Related]
11. Immunotherapies for advanced melanoma: as promising as they are expensive?
Garattini L; Padula A
J R Soc Med; 2017 Oct; 110(10):395-399. PubMed ID: 28871843
[No Abstract] [Full Text] [Related]
12. FDA approves new melanoma treatments.
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):3. PubMed ID: 22396993
[No Abstract] [Full Text] [Related]
13. [Medical therapy of malignant melanoma].
Mini E; Periti P
Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
[No Abstract] [Full Text] [Related]
14. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
15. Melanoma drug wins US approval.
Ledford H
Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
[No Abstract] [Full Text] [Related]
16. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
18. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
19. Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.
Errico A
Nat Rev Clin Oncol; 2015 Aug; 12(8):435. PubMed ID: 26099982
[No Abstract] [Full Text] [Related]
20. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]